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Both early- and late-onset noninfectious pulmonary injury are important contributors to the nonrelapse
mortality seen after allogeneic stem cell transplantation (allo-SCT), particularly in subjects conditioned with
high-dose total body irradiation (TBI). To characterize the kinetics of recovery from pulmonary injury in long-
term survivors, we collected data on 138 subjects who survived > 3 years (median survival, 10.2 years) after
predominantly TBI-based allo-SCT from their HLA-matched siblings. Baseline pulmonary function tests
served as the reference for subsequent measurements at 3, 5, 10, and 15 years for each survivor. The only
parameter showing a clinically and statistically signiﬁcant decline post-transplant was adjusted diffusion
capacity of lung for carbon monoxide (DLCO), which reached a nadir at 5 years but surprisingly normalized at
the 10-year mark. Multivariable modeling identiﬁed chronic graft-versus-host disease (P < .02) and abnormal
baseline-adjusted DLCO (P < .03) as the only signiﬁcant factors associated with the decline in adjusted DLCO
at 5 years but excluded smoking, conditioning intensity, baseline C-reactive protein level, TBI dose to the
lungs, disease, and demographic variables. In conclusion, pulmonary injury as monitored by the adjusted
DLCO continues to deteriorate in the ﬁrst 5 years after allo-SCT but recovers at 10 years.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION survivors beyond 3 years. This led us to conduct a landmark
Pulmonary injury isa frequentcomplicationafterallogeneic
stemcell transplantation (allo-SCT) and isa leading contributor
to nonrelapsemortality [1-10]. Previous studies have reported
that pulmonary function abnormalities are largely associated
with risk factors like smoking, total body irradiation (TBI),
and impaired pretransplant pulmonary function [6,11-17].
Serial pulmonary function testing is very important in the
detection and management of pulmonary injury.
We previously reported early- and intermediate-term
pulmonary complications in a cohort of subjects undergo-
ing predominantly myeloablative, full-dose, TBI-based con-
ditioning followed by T celledepleted HLA-identical sibling
grafts. In the ﬁrst year after allo-SCT, noninfectious pulmo-
nary injury was seen in >10% of subjects, with pulmonary
nonrelapse mortality occurring at a median of 90 days
(range, 23 to 238 days). Pretransplant diffusion capacity of
lungs for carbon monoxide (DLCO), smoking history, CD34þ
dose, and lung shielding were independent risk factors
[14,16]. With continued follow-up beyond the ﬁrst year
(median follow-up was 44 months), the median time to
pulmonary function test (PFT) decline was 37 months. Pre-
transplant DLCO or forced expiratory volume in 1 second
(FEV1) < 80% and chronic graft-versus-host disease (GVHD)
were independently associated with a decline in PFTs [15].
Interestingly, the adverse impact of TBI on PFTs was
restricted to the ﬁrst 2 years after SCT [16]. Much less data
are available on pulmonary late effects in long-term allo-SCTledgments on page 213.
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13.10.025analysis of subjects who were alive for more than 3 years
after allo-SCT. The objectives were to identify patterns of PFT
abnormality, study the kinetics of PFT decline, and identify
underlying factors contributing to late PFT decline.
METHODS
Patients and Study Design
We studied the PFTs of 138 survivors beyond a 3-year post-transplant
landmark who underwent allo-SCT from HLA-identical siblings at the He-
matology Branch of the National Heart, Lung, and Blood Institute at the
National Institutes of Health between September 1993 and September 2008.
All subjects gave written informed consent for long-term evaluation and
follow-up on a natural history protocol (NHLBI 05-H-0130; ClinicalTrials.gov
Identiﬁer NCT00106925). We conducted cross-sectional analyses at 3, 5, 10,
and 15 years post-transplant to characterize the kinetics of pulmonary
injury. Ninety-one patients were previously included in a study of early
pulmonary mortality [14], and 69 patients were previously reported in a
study of post-transplant PFT abnormalities with shorter follow-up [13].
Statistical Analysis
Summary statistics such as sample proportions, medians, standard de-
viations, and 95% conﬁdence intervals were used to describe patient char-
acteristics. Smoking, TBI dose delivered to the lungs, conditioning intensity,
baseline C-reactive protein level, chronic GVHD, all PFTs, and demographic
variables were entered into the multivariate model (forward-stepwise
multiple regression). Paired t-tests were used to compare 3-year, 5-year, 10-
year, and 15-year post-transplant observations to the pretransplant baseline
PFTs. Sensitivity analyses were conducted to examine the impact of the loss
of subjects in the cohort because of delayed mortality beyond 3 years and
the inﬂuence of late survivors at 15 years. Statistical signiﬁcance was
considered when P < .05. All statistical analyses were performed using IBM
SPSS v20 (SPSS Inc., Chicago, IL). Graphs were created using Prism 5.03
(GraphPad Software, Inc., La Jolla, CA).
Pulmonary Function Tests
Patients with baseline PFTs < 80% of their population reference were
considered abnormal at baseline. Because of variability in the populationSociety for Blood and Marrow Transplantation.
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inherent inaccuracy and assumptions related to such comparisons [18], we
followed themethod of Gore et al. [19] in using each subject’s baseline PFTas
the reference for all subsequent measurements at 3, 5, 10, and 15 years.
Baseline PFTs were obtained in all patients 5 to 21 days before allo-SCT.
Ventilation capacity was measured by forced vital capacity (FVC), FEV1, the
FEV1/FVC ratio, and peak expiratory ﬂow. Lung volume measurements (by
helium dilution) included vital capacity (VC), total lung capacity (TLC), re-
sidual volume, and the residual volume/TLC ratio. Gas exchange was
determined by DLCO by using a carbon monoxide single-breath technique
with correction for hemoglobin and alveolar ventilation (DLCO_Adj).
Because alveolar ventilation is decreased in restrictive lung disorders, the
ﬁndings for DLCO_Adj were conﬁrmed by comparison with DLCO without
this correction.
Pulmonary symptoms were not recorded prospectively for this study,
and we deﬁned a clinically signiﬁcant change as a>10% further decline from
their baseline PFT. PFTs were not performed in patients with recent in-
fections because of the risk of adversely confounding PFT results.
RESULTS
Patient Characteristics
Patient and transplant characteristics are summarized in
Table 1. The median age at transplant was 35 years. Most
subjects received high-dose TBIebased conditioning with T
celledepleted grafts from their HLA-matched siblings. In
subsequent years, patients older than 55 years were
restricted to 400 cGy of TBI and younger patients had their
dose of TBI reduced from 1360 cGy to 1200 cGy (with lungTable 1
Patient and Transplant Characteristics at Allo-SCT
Characteristic Percent
Gender
Female 56
Male 44
Ethnicity
Non-Hispanic 49
Hispanic 48
Not stated 2
Transplant indications
CML 46
AML 23
MDS 14
ALL 9
NHL/CLL 4
SAA 1.4
CMML 1.4
Mastocytosis .7
Graft source
PBSC (ex vivo T cell depleted) 81.9
Bone marrow 11.6
PBSC (unmanipulated) 6.5
Intensity of conditioning
Myeloablative 94.9
Nonmyeloablative 5.1
TBI (cGy)
0 6.5
400 2.2
1200-1360 91
TBI dose to lungs
0 6.5
400-600 35.5
900 15.2
1360 42.8
Busulfan exposure
Yes (all pretransplant) 4.0
No 96.0
Smoking history
Pretransplant 19.5
Post-transplant 12.2
ALL indicates acute lymphoid leukemia; AML, acute myelogenous leukemia;
CLL, chronic lymphoid leukemia; CMML, chronic myelomnocytic leukemia;
MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA, se-
vere aplastic anemia.shielding to 900 or 600 cGy). In addition to TBI, patients also
received cytoxan þ/ ﬂudarabine for conditioning.
Survivor Outcomes
At the time of analysis, 138 survivors were informative at
the baseline/pretransplant time point, and 123 at 3 years, 113
at 5 years, 63 at 10 years, and 8 at 15 years post-SCT. The
median survival was 10.2 years. Of the 16 patients who died
after 3 years, 4 (2.8%) died of pulmonary causes, including 2
who died of lung cancer (Table 2).
Our previous analyses of late effects in T celledepleted
transplantation have shown an impact when chronic GVHD
required the utilization of immunosuppressive therapy at 3
or more years post-transplant [13]. In this cohort, chronic
GVHD was generally mild, only 30% of subjects required
systemic immunosuppression at 3 years post-transplant,
and all patients were free of chronic GVHD at 5 and 10
years post-transplant. Pulmonary forms of GVHD, either
cryptogenic organizing pneumonia or bronchiolitis obliter-
ans syndrome were observed in only 3.6%. Post-transplant
smoking was conﬁrmed in 10.4% of the informative sub-
jects, but smoking data were only available for 35% of post-
transplant survivors.
Baseline PFT Abnormalities
Baseline abnormalities (<80% predicted) in PFTs were
found in 17.4% of subjects in the following declining fre-
quencies: FVC%, VC, TLC, FEV1, DLCO_Adj (adjusted for he-
moglobin and alveolar ventilation) hemoglobin/alveolar
ventilation, and FEV1/FVC. Abnormalities in a single
parameter were found in 5.8%, and abnormalities in mul-
tiple parameters were found in 11.6% of subjects. Baseline
PFT are shown in Figure 1.
Changes in PFTs Post-SCT
The lung volumes as measured by FEV1 (Figure 2A) and
lung capacity as measured by the VC (Figure 2B) and TLC
(Figure 2C) remained unchanged. The FEV1/FVC ratio
showed a statistically signiﬁcant decline that was not clin-
ically signiﬁcant (Figure 2D). The only parameter that
showed both a clinically and statistically signiﬁcant decline
post-transplant was DLCO_Adj which reached a nadir at 5
years, with subsequent normalization at the 10-year mark
(paired t-test). Abnormal (<80% predicted) DLCO_Adj was
found in 19.6%, 21.0%, .7%, and 0% of survivors at 3, 5, 10, and
15 years post-transplant, respectively. The mean DLCO_Adj
(Figure 3) at 3, 5, 10, and 15 years were 91% (P ¼ .003), 88%
(P ¼ .001), 98% (P ¼ NS), and 100% (P ¼ NS), respectively,
when compared with baseline. A similar kinetic for decline
and recovery was observed in DLCO without correction for
alveolar ventilation (Supplementary Figure 1). Taken
together with unchanged lung capacity measurements, this
suggests the subsequent improvement in diffusion capacityTable 2
Causes of Death in Long-Term Survivors Beyond 3 Years
Cause Number
Relapse 6 (4.3%)
Lung cancer 2 (1.4%)
Respiratory failure, pneumonia 2 (1.4%)
Other malignancy 2 (1.4%)
Nonpulmonary infections 2 (1.4%)
Brain hemorrhage 1 (.7%)
Chronic GVHD, multiorgan failure 1 (.7%)
Figure 1. Proportions of patients with abnormal (<80% of the predicted)
pretransplant PFTs. Proportions shown are not mutually exclusive.
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restrictive process (lung ﬁbrosis).
To exclude the possibility that the apparent improvement
in DLCO_Adj beyond 10 years was a survivorship bias due to
enrichment of survivors with better lung function, the
analysis was repeated on the subgroup of 8 patients with
data available at all time points (Figure 4A); a similar pattern
of DLCO_Adj kinetics conﬁrmed that inclusion of these sub-
jects did not skew the results. Another sensitivity analysis,
conducted in the 16 subjects who died beyond 3 years
(Figure 4B), showed little decline in diffusion capacity, sug-
gesting that loss of these subjects did not inﬂuence the
results.Figure 2. Lung volumes at baseline and at 5, 10, and 15 years post-transplant. A, trend
years post transplant. B, trend of vital capacity (VC) at baseline, 5, 10 and 15 years pos
post transplant. D, trend of FEV1/FVC ratio at baseline, 5, 10 and 15 years post transpRisk Factors for Decline in DLCO_Adj at 5 Years Post-
Transplant
We evaluated pre- and post-transplant smoking history,
conditioning intensity, radiation doses delivered to the lung
and the body, busulfan exposure, C-reactive protein levels,
disease, chronic GVHD, abnormal (<80% reference) baseline
DLC_Adj, and demographic variables in univariate and
multivariable models for their impact on DLCO. Busulfanwas
not used in our transplant conditioning regimens, but 4% of
subjects had prior busulfan exposure, which was not found
to inﬂuence the DLCO_Adj; pre- or post-transplant smoking
was also not found to inﬂuence the DLCO_Adj. In multivari-
able linear regression for the decline at DLCO_Adj at 5 years,
any chronic GVHD at 3 years post-transplant (P ¼ .017) and
abnormal DLCO_Adj at baseline (P ¼ .023) were the only
signiﬁcant factors associated with the decline in the
DLCO_Adj at 5 years. The model excluded smoking, lung TBI
dose, conditioning intensity, baseline C-reactive protein,
disease, and demographic variables (ethnicity, sex, and age).DISCUSSION
Pulmonary complications can represent one of the more
delayed complications of allo-SCT. Chronic GVHD is consid-
ered a major risk factor responsible for late pulmonary
complications and death. However, no extended studies have
tracked pulmonary functions beyond the ﬁrst decade after
SCT.We found that DLCO_Adjwas the only PFT that showed a
clinically signiﬁcant decline post-transplant, with a nadir at 5
years and, surprisingly, subsequent normalization at theof forced expiratory volume in the ﬁrst second (FEV1) at baseline, 5, 10 and 15
t transplant. C, trend of total lung capacity (TLC) at baseline, 5, 10 and 15 years
lant.
Figure 3. Mean DLCO adjusted for hemoglobin and alveolar ventilation at
baseline and at 3, 5, 10, and 15 years.
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vorship or attrition.
Decreased pulmonary function after SCT is considered a
poor prognostic marker of incipient pulmonary failure after
SCT. In this study of 138 patients, only 1 died of GVHD with
pulmonary involvement. In fact, although we saw continued
deterioration of pulmonary function up to 5 years, we
observed a surprising improvement at 10 years even in pa-
tients with chronic GVHD. These ﬁndings point to pulmonary
repair capacity of diffusion capacity, but notably therewas no
change in lung volumes or dynamic function as measured by
TLC, FEV1, and VC. The different ﬁnding of improved DLCO
suggests repair that mainly involves the alveolar membrane.
Without recourse to lung biopsy, we can only speculate on
the mechanisms of repair at the alveolar vascular interface.Figure 4. (A) Kinetics of recovery of DLCO adjusted for hemoglobin and alveolar venti
recovery of DLCO adjusted for hemoglobin and alveolar ventilation in the subjects wOther studies have demonstrated a signiﬁcant associa-
tion between poor pretransplant pulmonary function and
the risk for development of early respiratory failure and
mortality [11,13,19-23]. Chronic GVHD has also been asso-
ciated with declines in PFTs [13]. Our study extends the
importance of chronic GVHD at 3 years (despite rare lung
involvement) and baseline PFTs in the late post-transplant
period.
The rate of chronic GVHD in our cohort in this landmark
analysis was remarkably low, and pulmonary forms of GVHD,
either cryptogenic organizing pneumonia or bronchiolitis
obliterans syndrome, were observed in only 3.6%. However,
this should not imply that pulmonarymortality did not occur
in our transplanted patients. We previously reported that of
the 21 transplant-related deaths in a cohort of 146 new
transplants, 14 were from pulmonary causes (10 from idio-
pathic pulmonary syndromes and 4 from infection) occur-
ring at a median of 90 days (range, 23 to 238 days) after
transplantation [14]. This implies that most patients with
severe forms of pulmonary injury die early in the post-
transplant period, but those with sublethal injury may
recover their pulmonary function.
In our study, we used baseline PFTs of each patient as an
internal control for subsequent time points. Gore et al. [19]
also used pretransplant values as a basis for comparison
with post-transplant measurements. They found that FEV1,
FVC, and TLC were lower at 6 months and 1 year post-
transplant with subsequent recovery. DLCO adjusted for he-
moglobin was signiﬁcantly lower at all intervals and showed
an incomplete trend toward recovery [19].
We had earlier shown that TBI, with or without lung dose
reduction, has a small but statistically signiﬁcant effect on
PFTs at 1 year postetransplant but not at 2 years post-
transplant [16]. This study conﬁrms that TBI exerts no in-
ﬂuence on the decline in DLCO at 5 years.
In a pediatric study by Quigg et al. [24], low pretransplant
DLCO adjusted for both hemoglobin and alveolar volumewas
found to be predictive of death. They showed that PFTs were
signiﬁcantly lower at 1 year post-transplant but recovered at
2 years [24]. It is possible that the kinetics of PFT abnormality
are inﬂuenced by age, and ours was a predominantly adult
cohort.lation in the subjects who survived for 15 years post-transplant. (B) Kinetics of
ho died beyond 3 years post-transplant.
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mostly homogeneous group of subjects receiving high-dose
TBI-based ablative conditioning and T celledepleted grafts.
Signiﬁcant limitations to generalizability are related to our
cohort of patients. Most of our subjects (>80%) had received
an ex vivo T lymphocyteedepleted graft. It is likely that this
might have reduced the prevalence and severity of chronic
GVHD and mitigated pulmonary injury. This limits extrapo-
lation to other transplant settings, speciﬁcally the more
common T cellereplete grafts, mismatched transplants, and
unrelated donor transplantation, which are more likely to
have signiﬁcant chronic GVHD at later time points. The
relatively lower median age (35 years) and the preponder-
ance of chronic myelogenous leukemia as the transplant
indication are also very different from current trans-
plantation practice. Other limitations are the attrition of
subjects and incomplete smoking history.
In conclusion, our ﬁndings are important in revealing the
capacity of the tissues damaged by radiation or GVHD to heal
over time. The opportunity for lung repair post-SCT should
be taken into consideration when reviewing patients with
deteriorating pulmonary functions in the ﬁrst 5 years after
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